Advertisement

Topics

Latest "Somna Therapeutics LLC" News Stories

11:38 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "Somna Therapeutics LLC" found in our extensive news archives from over 250 global news sources.

More Information about Somna Therapeutics LLC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Somna Therapeutics LLC for you to read. Along with our medical data and news we also list Somna Therapeutics LLC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Somna Therapeutics LLC Companies for you to search.

Showing "Somna Therapeutics" News Articles 1–25 of 7,800+

Tuesday 25th September 2018

Obstructive Sleep Apnea Global Clinical Trials Review, H1, 2018 [Report Updated: 31032018] Prices from USD $2500

Obstructive Sleep Apnea Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Obstructive Sleep Apnea Global Clinical Trials Review, H1, 2018" provides an overview of Obstructive Sleep Apnea clinical trials scenario. This report provides top line data relating to the clinical trials on Obstructive Sleep Apnea. Report includes an overview of trial numbers and their avera...


$ALDX Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented At #ASLC18 https://finance.yahoo.com/news/aldeyra-therapeutics-announces-positive-mesothelioma-120000534.html …

$ALDX Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented At #ASLC18 https://finance.yahoo.com/news/aldeyra-therapeutics-announces-positive-mesothelioma-120000534.html …

Anaeropharma Science Signs Collaborative Research Agreement with Astellas on Creation of Novel Anti-Tumor Drugs Using Bifidobacterium

TOKYO, Sept. 25, 2018 /PRNewswire/ -- Anaeropharma Science Inc. headquartered in Tokyo (hereafter "Anaeropharma") announced on September 25 that Anaeropharma and Astellas Pharma Inc. headquartered in Tokyo (hereafter "Astellas") have concluded a collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes characteristic features of Bifidobact...


Wow, congrats Patrick! One of the founders of biotwitter making big things happen!! https://www.nasdaq.com/press-release/cerecor-to-acquire-ichorion-therapeutics-20180925-00220 …

Wow, congrats Patrick! One of the founders of biotwitter making big things happen!! https://www.nasdaq.com/press-release/cerecor-to-acquire-ichorion-therapeutics-20180925-00220 …

TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial http://www.globenewswire.com/news-release/2018/09/25/1575546/0/en/TG-Therapeutics-Announces-Update-Regarding-UNITY-CLL-Phase-3-Trial.html …. $TGTX

TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial http://www.globenewswire.com/news-release/2018/09/25/1575546/0/en/TG-Therapeutics-Announces-Update-Regarding-UNITY-CLL-Phase-3-Trial.html …. $TGTX

$TGTX Update Regarding UNITY-CLL Phase 3 Trial. DSMB advised the Company that the interim analysis of ORR could not be conducted at this time as the data were not sufficiently mature https://finance.yahoo.com/news/tg-therapeutics-announces-regarding-unity

$TGTX Update Regarding UNITY-CLL Phase 3 Trial. DSMB advised the Company that the interim analysis of ORR could not be conducted at this time as the data were not sufficiently mature https://finance.yahoo.com/news/tg-therapeutics-announces-regarding-unity-110000280.html …

STAT Plus: TG Therapeutics credibility vanishes with blood cancer drug trial setback

With another setback of its blood cancer drug trial, a New York biotech's credibility vanishes.

Hepatic Steatosis Across the Pediatric Age Spectrum

Is fatty liver disease more common in young children than previously thought? Using abdominal CT, this study investigated the prevalence of hepatic steatosis in a cohort of healthy children. Alimentary Pharmacology & Therapeutics

KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors

– Industry Leader Brings Expertise in Medical, Clinical and Regulatory Affairs in Drug Development – KSQ Therapeutics today announced the appointment of Richard A. Moscicki, MD, to the company’s Board of Directors. Dr. Moscicki brings more than 25 years of leadership experience in translational medicine, clinical development, regulatory af...

Millendo Therapeutics Appoints Habib Dable to Its Board of Directors

Millendo Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for orphan endocrine diseases, today announced the appointment of Habib Dable, President and Chief Executive Officer of Acceleron Pharma Inc., to the Company’s Board of Directors. “Habib brings to our board an exceptional mix of executive and ...

FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program

Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disea...

FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome

Myelo Therapeutics GmbH / FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. BERLIN, GERMANY, September 25, 2018 - Myelo Therapeutics GmbH announced today that the US Food and Drug Administration (FDA) has gr...

Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: The 14th Annual Meeting of the Oligonucleotide Therapeutics Society – Seattle, September 30-October 3, 2018 October 1, 9:20 a.m. PDT – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-...

Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics Through Clinical Proof of Concept

Series B financing led by Omega Funds and Novo Holdings Financing to enable the initiation of IND-enabling and clinical studies in 2019 Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that it has completed a $80 million Series B financing to fund its two lead programs through...

Keapstone satisfies conditions for further £1m investment

Virtual biotech Keapstone Therapeutics is in line for a further £1 million investment from Parkinson’s UK to move forward its innovative disease-modifying therapeutic approach to motor neuron disease (MND) and Parkinson’s.

$PSTI PR https://globenewswire.com/news-release/2018/09/25/1575478/0/en/Pluristem-Therapeutics-Announces-FDA-Orphan-Drug-Designation-for-PLX-cell-therapy-for-the-Treatment-of-Graft-Failure-and-Incomplete-Recovery-Following-Hematopoietic-Cell-Transplant.h

$PSTI PR https://globenewswire.com/news-release/2018/09/25/1575478/0/en/Pluristem-Therapeutics-Announces-FDA-Orphan-Drug-Designation-for-PLX-cell-therapy-for-the-Treatment-of-Graft-Failure-and-Incomplete-Recovery-Following-Hematopoietic-Cell-Transplant.html … https://twitter.com/odibro/status/1044317210079109123 …

Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease

Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease. This first-in-class compound modulates a novel protein target selectively expressed in an...

FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome

Myelo Therapeutics GmbH announced today that the US Food and Drug Administration has granted an Orphan Drug Designation to its orally applied new chemical entity Myelo001 for the treatment of Acute Radiation Syndrome.

WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board

SHANGHAI, Sept. 25, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the appointment of David R. Liu, Professor of Chemistry and Chemical Biology at Harvard University, Richard Merkin Professor and Vice-Chair of the Faculty at the Br...

Acer Therapeutics' Focus On Rare And Ultra-Rare Diseases: A Potentially Lucrative Business Model

Advicenne Prepares its Expansion with Highly Experienced Industry Professionals

Charlotte Sibley joins the Board of Directors as Independent Member Paul Michalet is appointed as Chief Financial Officer Regulatory News: Advicenne (Paris:ADVIC) (Euronext: ADVIC), a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal a...

FDA Nod For VSTM, ANAB Breathes Easy, GEMP Trims Workforce By 33%

Today's Daily Dose brings you news about AnaptysBio's (ANAB) trial results of Etokimab in adult patients with severe eosinophilic asthma; near-term catalyst of Audentes Therapeutics; lifting of partial clinical hold that was slapped on Epizyme's Tazemetostat clinical trials; workforce reduction in Gemphire and FDA approval of Verastem's COPIKTRA.

Monday 24th September 2018

ADDEX THERAPEUTICS RECOGNISED IN FINAL SHORTLIST FOR DEAL OF THE YEAR AT LIFESTARS AWARDS LIFE SCIENCE AWARDS FOR PARTNERSHIP WITH INDIVIOR

Geneva, Switzerland and London, UK, 25 September 2018 – Addex Therapeutics (SIX: ADXN), a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders, announced today that it has been recognised in the final shortlist of 10 European companies in the Deal of the Year category at the 2018 Lifestars AwardsTM for ...

Minomic Announces Completion of Demerger of GlyTherix Ltd

Demerger clears the path for therapeutic company capital raising Minomic International Ltd is pleased to announce it received strong shareholder approval to approve the demerger of its therapeutic subsidiary, GlyTherix Ltd, at a recent extraordinary general meeting. The demerger follows deep consultation with the investment community and poten...

Venus Medtech Launches Global Advisory Board to Target for International Market

SAN DIEGO, Sept. 25, 2018 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc., a Chinese medical device company specializing in transcatheter valve replacement therapy, has retained four world-renowned experts specialized in interventional cardiovascular to form a Global Advisory Board. The Board members will contribute their insights to Venus Medtech on global innovation of interventional car...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks